Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Carisma Therapeutics develops engineered macrophage and monocyte therapies for cancer and liver fibrosis. Its platform leverages CAR technology and mRNA/LNP delivery to create off-the-shelf and in vivo treatments targeting solid tumors and fibrotic diseases. The company collaborates with Moderna on in vivo CAR-M programs and owns a broad intellectual property portfolio, focusing on immuno-oncology and immunologic diseases with potential for milestone and royalty revenues.
This description was generated via AI from an annual report. Updated about 1 year ago.